首頁 > 市場調查報告書 > 製藥

亞太地區鴉片類藥物市場預測至 2030 年 - 區域分析 - 按產品、應用、給藥途徑和配銷通路

市場調查報告書

商品編碼

1637658

亞太地區鴉片類藥物市場預測至 2030 年 - 區域分析 - 按產品、應用、給藥途徑和配銷通路

Asia Pacific Opioids Market Forecast to 2030 - Regional Analysis - by Product, Application, Route of Administration, and Distribution Channel

出版日期: 2024年11月22日 | 出版商:

The Insight Partners | 英文 93 Pages | 訂單完成後即時交付

價格

簡介目錄圖表

2022年亞太地區鴉片類藥物市值為24.0624億美元，預計2030年將達到30.9177億美元；預計2022年至2030年複合年成長率為3.2%。

慢性疼痛發生率激增推動亞太鴉片類藥物市場

心血管疾病、癌症、肌肉骨骼疾病和神經血管疾病等慢性疾病會降低免疫力，嚴重影響人的健康。此外，許多患有這些病症的患者會經歷慢性疼痛。上述疾病在成人和老年族群中最常見。然而，兒童中這些疾病的病例也明顯增加。慢性疼痛在運動員、運動員和曾經受傷的人中也很常見。根據NCBI（即國家生物技術資訊中心）發表的一項研究，全世界有20%的成年人患有疼痛，並且每年有10%新診斷出患有慢性疼痛。雖然疼痛影響所有人群，無論性別、種族/民族、收入、年齡或地理位置如何，但疼痛在世界各地的分佈並不均勻。處方鴉片類藥物，包括氫可酮、羥考酮和嗎啡，是有效的止痛藥物，用於治療因受傷、手術以及癌症和關節炎等健康狀況引起的疼痛。

鴉片類藥物處方實踐的增加可歸因於保險報銷計劃，該計劃激勵鴉片類藥物而不是替代性疼痛治療、鼓勵更有效護理的成本結構以及將患者滿意度與有效疼痛管理相結合的評估。因此，由於鴉片類藥物在疼痛管理方面的優勢，對慢性病患者的需求不斷上升。

亞太地區鴉片類藥物市場概況

據估計，中國患有末期疾病的老年人口不斷增加，對鴉片類藥物的需求將大幅增加。根據世界衛生組織（WHO）的數據，該國是老齡化人口成長最快的國家之一。根據同一來源，2019 年 60 歲及以上人口為 2.54 億，65 歲及以上人口為 1.76 億。此外，由於預期壽命的延長和出生率的下降，預計到 2040 年，中國約 28% 的人口（4.02 億人）將年齡在 60 歲及以上。老年族群更有可能患有與疼痛相關的慢性健康問題，例如關節炎、背痛、癌症等。重大影響中國太平洋鴉片類藥物市場。在中國，新發患有嚴重病理性疼痛的癌症患者數量顯著增加。根據 2020 年發表的一項研究《醫生繼續醫學教育對中國癌痛治療品質的影響》，中國政府鼓勵使用鴉片類鎮痛藥治療中度至重度癌痛，這是廣泛應用於全國三級醫院、二級醫院。由於鴉片類藥物是三步驟鎮痛階梯的主要組成部分，建議用於緩解中度和重度癌症疼痛，因此提高對此類醫療狀況和相關治療的認知可以改善癌症疼痛的治療計劃。

亞太地區鴉片類藥物市場收入及 2030 年預測（百萬美元）

亞太地區鴉片類藥物市場細分

亞太地區鴉片類藥物市場按產品、應用、給藥途徑、配銷通路和國家分類。

根據產品，亞太地區鴉片類藥物市場分為速釋短效鴉片類藥物和緩釋長效型鴉片類藥物。 2022年，速釋短效鴉片類藥物細分市場佔據了更大的市場佔有率。芬等。緩釋長效型鴉片類藥物進一步細分為羥考酮、芬太尼、嗎啡、美沙酮等。

從應用來看，亞太地區鴉片類藥物市場分為疼痛管理、麻醉、止瀉、止咳、戒癮等。 2022 年，疼痛管理領域佔據最大的市場。

依給藥途徑，亞太地區鴉片類藥物市場分為口服、注射及經皮貼片。 2022 年，口腔細分市場佔據最大的市場佔有率。

按配銷通路分類，亞太地區鴉片類藥物市場分為醫院藥房和零售藥房。 2022年，醫院藥局部門將佔據更大的市場佔有率。

按國家/地區分類，亞太地區鴉片類藥物市場分為中國、日本、印度、韓國、澳洲和亞太其他地區。 2022年，中國在亞太鴉片類藥物市場佔有率中佔據主導地位。

Endo International plc、Mallinckrodt Plc、Neuraxpharm Pharmaceuticals SL、Mayne Pharma Group Ltd、Rusan Pharma Ltd 和 Teva Pharmaceutical Industries Ltd 是亞太鴉片類藥物市場上的一些領先公司。

Chronic diseases such as cardiovascular disease, cancer, musculoskeletal diseases, and neurovascular diseases critically affect a person's health by lowering immunity. Moreover, many patients suffering from these conditions experiences chronic pain. The diseases mentioned above are most common in adults and the geriatric population. Nevertheless, cases of these diseases are noticeably growing among children as well. Chronic pain is also common among sportspersons, athletes, and individuals living with past injuries. According to a study published in the NCBI (i.e., National Center for Biotechnology Information), 20% of adults suffer from pain worldwide, and 10% are newly diagnosed with chronic pain per year. While pain affects all populations, regardless of sex, race/ethnicity, income, age, or geography, it is not distributed equally across the world. Prescription opioids, including hydrocodone, oxycodone, and morphine, are potent pain-reducing medications that are used to treat pain caused by injuries, surgeries, and health conditions such as cancer and arthritis.

Increased opioid prescribing practices can be attributed to the insurance reimbursement programs that incentivize opioids over alternative pain treatments, cost structures that encourage more efficient care, and evaluations that combine patient satisfaction with effective pain management. Therefore, owing to the advantage of opioids in pain management, the demand is rising among patients with chronic diseases.

Asia Pacific Opioids Market Overview

The growing geriatric population in China suffering from terminal illnesses is estimated to significantly increase the demand for opioids. As per the World Health Organization (WHO), the country has one of the fastest-growing aging populations. Per the same source, 254 million people were aged 60 and above in 2019 and 176 million people were aged 65 and above. Also, ~28% of the population (402 million people) in China is expected to be aged 60 and above by 2040 due to increasing life expectancy and decreasing birth rates. Geriatric populations are more likely to experience chronic health conditions that are associated with pain, such as arthritis, back pain, cancer, etc. In such cases, opioids are used to manage chronic pain in older adults, which significantly influence the growth of the Asia Pacific opioids market in China. In China, the number of new cancer patients suffering from severe pathological pain has significantly increased. As per a study, "Impact of Continuing Medical Education for Physicians on the Quality of Cancer Pain Treatment in China," published in 2020, the government of China encourages the use of opioid analgesics for the treatment of moderate to severe cancer pain, which is widely available in tertiary hospitals and secondary hospitals across the country. As opioids are a major part of a three-step analgesic ladder and are recommended for relieving moderate and severe cancer pain, increasing awareness regarding such medical conditions and associated treatment can improve the treatment plan for cancer pain.

Asia Pacific Opioids Market Revenue and Forecast to 2030 (US$ Million)

Asia Pacific Opioids Market Segmentation

The Asia Pacific opioids market is categorized into product, application, route of administration, distribution channel, and country.

Based on product, the Asia Pacific opioids market is segmented immediate release short acting opioid and extended release long acting opioid. The immediate release short acting opioid segment held a larger market share in 2022. The immediate release short acting opioid is further sub segmented into oxycodone, hydrocodone, tramadol, codeine, propoxyphene, and others. The extended release long acting opioid is further sub segmented into oxycodone, fentanyl, morphine, methadone, and others.

In terms of application, the Asia Pacific opioids market is categorized into pain management, anesthesia, diarrhea suppression, cough suppression, de-addiction, and others. The pain management segment held the largest market share in 2022.

By route of administration, the Asia Pacific opioids market is segmented into oral, injectable, and transdermal patch. The oral segment held the largest market share in 2022.

By distribution channel, the Asia Pacific opioids market is bifurcated into hospital pharmacies and retail pharmacies. The hospital pharmacies segment held a larger market share in 2022.

By country, the Asia Pacific opioids market is segmented into China, Japan, India, South Korea, Australia, and the Rest of Asia Pacific. China dominated the Asia Pacific opioids market share in 2022.

Endo International plc, Mallinckrodt Plc, Neuraxpharm Pharmaceuticals SL, Mayne Pharma Group Ltd, Rusan Pharma Ltd, and Teva Pharmaceutical Industries Ltd are some of the leading companies operating in the Asia Pacific opioids market.

1. Introduction

1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation

2. Executive Summary

2.1 Key Insights

3. Research Methodology

3.1 Coverage
3.2 Secondary Research
3.3 Primary Research

4. Asia Pacific Opioids Market - Key Market Dynamics

4.1 Market Drivers
- 4.1.1 Surging Chronic Pain Incidence
- 4.1.2 Increasing Geriatric Population
4.2 Market Restraints
- 4.2.1 Increasing Drug Abuse
4.3 Market Opportunities
- 4.3.1 Strategic Initiatives by Market Players
4.4 Impact of Drivers and Restraints:

5. Opioids Market - Asia Pacific Analysis

5.1 Asia Pacific Opioids Market Overview
5.2 Asia Pacific Opioids Market Revenue (US$ Million), 2020-2030
5.3 Asia Pacific Opioids Market Forecast Analysis

6. Asia Pacific Opioids Market Analysis - by Product

6.1 Immediate Release Short Acting Opioid
- 6.1.1 Overview
- 6.1.2 Immediate Release Short Acting Opioid: Asia Pacific Opioids Market - Revenue and Forecast to 2030 (US$ Million)
  - 6.1.2.1 Asia Pacific Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Immediate Release Short Acting Opioid
6.2 Extended Release Long-Acting Opioid
- 6.2.1 Overview
- 6.2.2 Extended Release Long-Acting Opioid: Asia Pacific Opioids Market - Revenue and Forecast to 2030 (US$ Million)
  - 6.2.2.1 Asia Pacific Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Extended Release Long-Acting Opioid

7. Asia Pacific Opioids Market Analysis - by Application

7.1 Pain Management
- 7.1.1 Overview
- 7.1.2 Pain Management: Asia Pacific Opioids Market - Revenue and Forecast to 2030 (US$ Million)
7.2 Anesthesia
- 7.2.1 Overview
- 7.2.2 Anesthesia: Asia Pacific Opioids Market - Revenue and Forecast to 2030 (US$ Million)
7.3 Diarrhea Suppression
- 7.3.1 Overview
- 7.3.2 Diarrhea Suppression: Asia Pacific Opioids Market - Revenue and Forecast to 2030 (US$ Million)
7.4 Cough Suppression
- 7.4.1 Overview
- 7.4.2 Cough Suppression: Asia Pacific Opioids Market - Revenue and Forecast to 2030 (US$ Million)
7.5 De-Addiction
- 7.5.1 Overview
- 7.5.2 De-Addiction: Asia Pacific Opioids Market - Revenue and Forecast to 2030 (US$ Million)
7.6 Others
- 7.6.1 Overview
- 7.6.2 Others: Asia Pacific Opioids Market - Revenue and Forecast to 2030 (US$ Million)

8. Asia Pacific Opioids Market Analysis - by Route of Administration

8.1 Oral
- 8.1.1 Overview
- 8.1.2 Oral: Asia Pacific Opioids Market - Revenue and Forecast to 2030 (US$ Million)
8.2 Injectable
- 8.2.1 Overview
- 8.2.2 Injectable: Asia Pacific Opioids Market - Revenue and Forecast to 2030 (US$ Million)
8.3 Transdermal Patch
- 8.3.1 Overview
- 8.3.2 Transdermal Patch: Asia Pacific Opioids Market - Revenue and Forecast to 2030 (US$ Million)

9. Asia Pacific Opioids Market Analysis - by Distribution Channel

9.1 Hospital Pharmacies
- 9.1.1 Overview
- 9.1.2 Hospital Pharmacies: Asia Pacific Opioids Market - Revenue and Forecast to 2030 (US$ Million)
9.2 Retail Pharmacies
- 9.2.1 Overview
- 9.2.2 Retail Pharmacies: Asia Pacific Opioids Market - Revenue and Forecast to 2030 (US$ Million)

10. Asia Pacific Opioids Market - Country Analysis

10.1 Asia Pacific
- 10.1.1 Asia Pacific: Opioids Market Breakdown, by Key Countries, 2022 and 2030 (%)
  - 10.1.1.1 Asia Pacific: Opioids Market - Revenue and Forecast Analysis - by Country
  - 10.1.1.2 China: Asia Pacific Opioids Market - Revenue and Forecast to 2030 (US$ Million)
    - 10.1.1.2.1 China: Asia Pacific Opioids Market Breakdown, by Product
    - 10.1.1.2.2 China: Asia Pacific Opioids Market Breakdown, by Immediate Release Short Acting Opioid
    - 10.1.1.2.3 China: Asia Pacific Opioids Market Breakdown, by Extended Release Long-Acting Opioid
    - 10.1.1.2.4 China: Asia Pacific Opioids Market Breakdown, by Application
    - 10.1.1.2.5 China: Asia Pacific Opioids Market Breakdown, by Route of Administration
    - 10.1.1.2.6 China: Asia Pacific Opioids Market Breakdown, by Distribution Channel
  - 10.1.1.3 Japan: Asia Pacific Opioids Market - Revenue and Forecast to 2030 (US$ Million)
    - 10.1.1.3.1 Japan: Asia Pacific Opioids Market Breakdown, by Product
    - 10.1.1.3.2 Japan: Asia Pacific Opioids Market Breakdown, by Immediate Release Short Acting Opioid
    - 10.1.1.3.3 Japan: Asia Pacific Opioids Market Breakdown, by Extended Release Long-Acting Opioid
    - 10.1.1.3.4 Japan: Asia Pacific Opioids Market Breakdown, by Application
    - 10.1.1.3.5 Japan: Asia Pacific Opioids Market Breakdown, by Route of Administration
    - 10.1.1.3.6 Japan: Asia Pacific Opioids Market Breakdown, by Distribution Channel
  - 10.1.1.4 India: Asia Pacific Opioids Market - Revenue and Forecast to 2030 (US$ Million)
    - 10.1.1.4.1 India: Asia Pacific Opioids Market Breakdown, by Product
    - 10.1.1.4.2 India: Asia Pacific Opioids Market Breakdown, by Immediate Release Short Acting Opioid
    - 10.1.1.4.3 India: Asia Pacific Opioids Market Breakdown, by Extended Release Long-Acting Opioid
    - 10.1.1.4.4 India: Asia Pacific Opioids Market Breakdown, by Application
    - 10.1.1.4.5 India: Asia Pacific Opioids Market Breakdown, by Route of Administration
    - 10.1.1.4.6 India: Asia Pacific Opioids Market Breakdown, by Distribution Channel
  - 10.1.1.5 South Korea: Asia Pacific Opioids Market - Revenue and Forecast to 2030 (US$ Million)
    - 10.1.1.5.1 South Korea: Asia Pacific Opioids Market Breakdown, by Product
    - 10.1.1.5.2 South Korea: Asia Pacific Opioids Market Breakdown, by Immediate Release Short Acting Opioid
    - 10.1.1.5.3 South Korea: Asia Pacific Opioids Market Breakdown, by Extended Release Long-Acting Opioid
    - 10.1.1.5.4 South Korea: Asia Pacific Opioids Market Breakdown, by Application
    - 10.1.1.5.5 South Korea: Asia Pacific Opioids Market Breakdown, by Route of Administration
    - 10.1.1.5.6 South Korea: Asia Pacific Opioids Market Breakdown, by Distribution Channel
  - 10.1.1.6 Australia: Asia Pacific Opioids Market - Revenue and Forecast to 2030 (US$ Million)
    - 10.1.1.6.1 Australia: Asia Pacific Opioids Market Breakdown, by Product
    - 10.1.1.6.2 Australia: Asia Pacific Opioids Market Breakdown, by Immediate Release Short Acting Opioid
    - 10.1.1.6.3 Australia: Asia Pacific Opioids Market Breakdown, by Extended Release Long-Acting Opioid
    - 10.1.1.6.4 Australia: Asia Pacific Opioids Market Breakdown, by Application
    - 10.1.1.6.5 Australia: Asia Pacific Opioids Market Breakdown, by Route of Administration
    - 10.1.1.6.6 Australia: Asia Pacific Opioids Market Breakdown, by Distribution Channel
  - 10.1.1.7 Rest of Asia Pacific: Asia Pacific Opioids Market - Revenue and Forecast to 2030 (US$ Million)
    - 10.1.1.7.1 Rest of Asia Pacific: Asia Pacific Opioids Market Breakdown, by Product
    - 10.1.1.7.2 Rest of Asia Pacific: Asia Pacific Opioids Market Breakdown, by Immediate Release Short Acting Opioid
    - 10.1.1.7.3 Rest of Asia Pacific: Asia Pacific Opioids Market Breakdown, by Extended Release Long-Acting Opioid
    - 10.1.1.7.4 Rest of Asia Pacific: Asia Pacific Opioids Market Breakdown, by Application
    - 10.1.1.7.5 Rest of Asia Pacific: Asia Pacific Opioids Market Breakdown, by Route of Administration
    - 10.1.1.7.6 Rest of Asia Pacific: Asia Pacific Opioids Market Breakdown, by Distribution Channel

11. Industry Landscape

11.1 Overview
11.2 Growth Strategies in Opioids Market
11.3 Organic Growth Strategies
- 11.3.1 Overview
11.4 Inorganic Growth Strategies
- 11.4.1 Overview

12. Company Profiles

12.1 Endo International plc
- 12.1.1 Key Facts
- 12.1.2 Business Description
- 12.1.3 Products and Services
- 12.1.4 Financial Overview
- 12.1.5 SWOT Analysis
- 12.1.6 Key Developments
12.2 Mallinckrodt Plc
- 12.2.1 Key Facts
- 12.2.2 Business Description
- 12.2.3 Products and Services
- 12.2.4 Financial Overview
- 12.2.5 SWOT Analysis
- 12.2.6 Key Developments
12.3 Neuraxpharm Pharmaceuticals SL
- 12.3.1 Key Facts
- 12.3.2 Business Description
- 12.3.3 Products and Services
- 12.3.4 Financial Overview
- 12.3.5 SWOT Analysis
- 12.3.6 Key Developments
12.4 Mayne Pharma Group Ltd
- 12.4.1 Key Facts
- 12.4.2 Business Description
- 12.4.3 Products and Services
- 12.4.4 Financial Overview
- 12.4.5 SWOT Analysis
- 12.4.6 Key Developments
12.5 Rusan Pharma Ltd
- 12.5.1 Key Facts
- 12.5.2 Business Description
- 12.5.3 Products and Services
- 12.5.4 Financial Overview
- 12.5.5 SWOT Analysis
- 12.5.6 Key Developments
12.6 Teva Pharmaceutical Industries Ltd
- 12.6.1 Key Facts
- 12.6.2 Business Description
- 12.6.3 Products and Services
- 12.6.4 Financial Overview
- 12.6.5 SWOT Analysis
- 12.6.6 Key Developments

13. Appendix

13.1 About The Insight Partners
13.2 Glossary of Terms

簡介目錄圖表

List Of Tables

Table 1. Asia Pacific Opioids Market Segmentation
Table 2. Asia Pacific Opioids Market - Revenue and Forecast to 2030 (US$ Million)
Table 3. Asia Pacific Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Product
Table 4. Asia Pacific Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Immediate Release Short Acting Opioid
Table 5. Asia Pacific Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Extended Release Long-Acting Opioid
Table 6. Asia Pacific Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Application
Table 7. Asia Pacific Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Route of Administration
Table 8. Asia Pacific Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Distribution Channel
Table 9. Asia Pacific: Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Country
Table 10. China: Asia Pacific Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Product
Table 11. China: Asia Pacific Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Immediate Release Short Acting Opioid
Table 12. China: Asia Pacific Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Extended Release Long-Acting Opioid
Table 13. China: Asia Pacific Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Application
Table 14. China: Asia Pacific Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Route of Administration
Table 15. China: Asia Pacific Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Distribution Channel
Table 16. Japan: Asia Pacific Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Product
Table 17. Japan: Asia Pacific Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Immediate Release Short Acting Opioid
Table 18. Japan: Asia Pacific Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Extended Release Long-Acting Opioid
Table 19. Japan: Asia Pacific Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Application
Table 20. Japan: Asia Pacific Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Route of Administration
Table 21. Japan: Asia Pacific Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Distribution Channel
Table 22. India: Asia Pacific Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Product
Table 23. India: Asia Pacific Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Immediate Release Short Acting Opioid
Table 24. India: Asia Pacific Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Extended Release Long-Acting Opioid
Table 25. India: Asia Pacific Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Application
Table 26. India: Asia Pacific Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Route of Administration
Table 27. India: Asia Pacific Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Distribution Channel
Table 28. South Korea: Asia Pacific Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Product
Table 29. South Korea: Asia Pacific Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Immediate Release Short Acting Opioid
Table 30. South Korea: Asia Pacific Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Extended Release Long-Acting Opioid
Table 31. South Korea: Asia Pacific Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Application
Table 32. South Korea: Asia Pacific Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Route of Administration
Table 33. South Korea: Asia Pacific Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Distribution Channel
Table 34. Australia: Asia Pacific Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Product
Table 35. Australia: Asia Pacific Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Immediate Release Short Acting Opioid
Table 36. Australia: Asia Pacific Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Extended Release Long-Acting Opioid
Table 37. Australia: Asia Pacific Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Application
Table 38. Australia: Asia Pacific Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Route of Administration
Table 39. Australia: Asia Pacific Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Distribution Channel
Table 40. Rest of Asia Pacific: Asia Pacific Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Product
Table 41. Rest of Asia Pacific: Asia Pacific Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Immediate Release Short Acting Opioid
Table 42. Rest of Asia Pacific: Asia Pacific Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Extended Release Long-Acting Opioid
Table 43. Rest of Asia Pacific: Asia Pacific Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Application
Table 44. Rest of Asia Pacific: Asia Pacific Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Route of Administration
Table 45. Rest of Asia Pacific: Asia Pacific Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Distribution Channel
Table 46. Recent Organic Growth Strategies in Opioids Market
Table 47. Recent Inorganic Growth Strategies in the Opioids Market
Table 48. Glossary of Terms, Opioids Market

List Of Figures

Figure 1. Asia Pacific Opioids Market Segmentation, by Country
Figure 2. Asia Pacific Opioids Market - Key Market Dynamics
Figure 3. Impact Analysis of Drivers and Restraints
Figure 4. Asia Pacific Opioids Market Revenue (US$ Million), 2020-2030
Figure 5. Asia Pacific Opioids Market Share (%) - by Product (2022 and 2030)
Figure 6. Immediate Release Short Acting Opioid: Asia Pacific Opioids Market - Revenue and Forecast to 2030 (US$ Million)
Figure 7. Extended Release Long-Acting Opioid: Asia Pacific Opioids Market - Revenue and Forecast to 2030 (US$ Million)
Figure 8. Asia Pacific Opioids Market Share (%) - by Application (2022 and 2030)
Figure 9. Pain Management: Asia Pacific Opioids Market - Revenue and Forecast to 2030 (US$ Million)
Figure 10. Anesthesia: Asia Pacific Opioids Market - Revenue and Forecast to 2030 (US$ Million)
Figure 11. Diarrhea Suppression: Asia Pacific Opioids Market - Revenue and Forecast to 2030 (US$ Million)
Figure 12. Cough Suppression: Asia Pacific Opioids Market - Revenue and Forecast to 2030 (US$ Million)
Figure 13. De-Addiction: Asia Pacific Opioids Market - Revenue and Forecast to 2030 (US$ Million)
Figure 14. Others: Asia Pacific Opioids Market - Revenue and Forecast to 2030 (US$ Million)
Figure 15. Asia Pacific Opioids Market Share (%) - by Route of Administration (2022 and 2030)
Figure 16. Oral: Asia Pacific Opioids Market - Revenue and Forecast to 2030 (US$ Million)
Figure 17. Injectable: Asia Pacific Opioids Market - Revenue and Forecast to 2030 (US$ Million)
Figure 18. Transdermal Patch: Asia Pacific Opioids Market - Revenue and Forecast to 2030 (US$ Million)
Figure 19. Asia Pacific Opioids Market Share (%) - by Distribution Channel (2022 and 2030)
Figure 20. Hospital Pharmacies: Asia Pacific Opioids Market - Revenue and Forecast to 2030 (US$ Million)
Figure 21. Retail Pharmacies: Asia Pacific Opioids Market - Revenue and Forecast to 2030 (US$ Million)
Figure 22. Asia Pacific: Opioids Market, by Key Countries - Revenue (2022) (US$ Million)
Figure 23. Asia Pacific: Opioids Market Breakdown, by Key Countries, 2022 and 2030 (%)
Figure 24. China: Asia Pacific Opioids Market - Revenue and Forecast to 2030 (US$ Million)
Figure 25. Japan: Asia Pacific Opioids Market - Revenue and Forecast to 2030 (US$ Million)
Figure 26. India: Asia Pacific Opioids Market - Revenue and Forecast to 2030 (US$ Million)
Figure 27. South Korea: Asia Pacific Opioids Market - Revenue and Forecast to 2030 (US$ Million)
Figure 28. Australia: Asia Pacific Opioids Market - Revenue and Forecast to 2030 (US$ Million)
Figure 29. Rest of Asia Pacific: Asia Pacific Opioids Market - Revenue and Forecast to 2030 (US$ Million)
Figure 30. Growth Strategies in Opioids Market